Skip to main content
. 2022 Nov 28;19(11):894–927. doi: 10.11909/j.issn.1671-5411.2022.11.008

Table 3. Review of studies on smoking in the elderly.

Studies Quality assessment Summary of findings Quality
Ref N Study
design
Limitations Inconsistency Indirectness Imprecision Publication
bias
Relative effect estimates Absolute
effect
estimates
CI: confidence Interval; COGTEL: Cognitive Telephone Screening Instrument; COPD: chronic obstructive pulmonary disease; CS: cohort study; CV: cardiovascular; CVD: cardiovascular disease; COGTEL: Cognitive Telephone Screening Instrument; COPD: chronic obstructive pulmonary disease; EXS: exsmokers; HR: Hazard ratio; I: Important; m: men;NA: no applicable; NS: non smoking; OBS: observational study; OR: odds ratio; RCT: random clinical trial; Ref: bibliography reference annex 1; RR: relative risk; RV: Review; S: smokers; SR: systematic review; U: Undetected; UV: unavailable; VI: very important; QALY: quality-adjusted life year; Quality: quality assessed according to GRADE methodology; w: women.
Does smoking affect cardiovascular disease in the elderly?
21 1 412 749 CS U I NA I U
HR 1.48 (95% CI. 1.15-1.90) (angina and acute coronary syndrome)
UV Low
22 8 807 CS U I NA I U HR 2.25 (CI 95%; 1.05-4.81) (NS. 50-59years)
HR 0.9 (0.63-1.29) (NS. 60-74years)
UV Low
Does smoking affect quality of life in the elderly?
23 3 652 CS U I NA U U -3.5 QALY (EXS) vs -8.8 QALY (NS) UV Low
24
382
CS
I

U

NA

U

U
Physical problems (carrying, climbing stairs, and walking)
OR (3.71-6.6-2.34) (NS)
OR (7.32-3.39-3.74) (NS <10years)
OR (4.53-3.35-2.66) (NS >11years)
UV Very low
Does smoking affect cognition in the elderly?
25 UV RS U I NA U U S vs EXS-NS: Alzheimer 1.59 (1.15-2.2) vs 0.99 (0.81-1.23)
Vascular dementia 1.35 (0.9-2.02) vs 1.05 (0.72-1.54)
Inespecific dementia 1.16 (0.9-1.5) vs 0.9 (0.75-1.07)
Cognitive decline 1.2 (0.9-1.59) vs 0.9 (0.74-1.1)
UV High
26 1 697 CS I U NA U U COGTEL -0.31 pts (-0.51.-0.11) (20 pack/year)
COGTEL -2 pts (-3.59; -0.4) (S vs NS)
UV Low
Does smoking affect mortality in the elderly?
27 UV SR I I NA U U Relative mortality: 1.83 (95% CI 1.65-2.03) (S vs NS)
vs 1.34 (1.28-1.34) (EXS vs NS)
UV Low
28 13 030 CS U U NA I U Relative mortality: 2.61 (95%CI 2.15-3.18) (S vs Ns)
Relative mortality CVC:
2.67 (1.92-2.67) and 1.95 (1.33-2.86) (m 45-64 and 65-74 years) vs
4.28 (2.29-7.99) and 2.67 (1.28-5.58) (w 45-64 and 65-74)
Cancer:
3 (2.15-4.18) and 4.5 (2.82-6.10) (NS m 45-64 and 65-74 years) vs
2.27 (1.64-3.44) and 4.45 (2.5-7.93) (NS. w. 45-64 and 65-74 years)
UV High
29 478 248 CS U I NA U U CVD mortality:
HR 1.82 (1.45-2.28) (NS 40 years) HR 0.96 (0.67-1.38) (NS 80 years)
Non-CVD mortality:
HR 1.69 (1.57-1.82) (NS 50 years) HR 1.4 (1.17-1.69) (NS 80 years)
UV Low
30 503 905 CS I VI NA U U CVD mortality: HR 2.07 (CI 95% 1.38-2.39) (NS)
Acuye coronary syndrome:
HR 1.98 (1.75-2.25) (NS) vs HR 1.18(1.06-1.32) (NS/ EXS)
stroke: HR 1.58 (1.4-1.78) (NS) vs HR 1.17 (1.07-1.26) (NS/ EXS)
UV High
Is it beneficial to quit smoking in older people?
31 267 010 OBS I U NA U U COPD risk hospitalization: HR 6.81 (CI95%: 5.87-7.89) (NS/ EXS)
General risk hospitalization:
HR 0.84 (95% CI. 0.82-0.86) 16% (c/10 years smoking cessation)
UV Low
32 95 683 CS I I NA I U Stroke (NS/ EXS): RR 1.39 (95%CI 1.13-1.70) (m) vs RR 1.65 (1.21-2.25) (w)
Acute coronary syndrome (NS/ EXS): RR 1.6 (1.39-1.84) (m) vs RR 3.35 (2.23-5-02) (w)
CVD total (NS/ EXS)
RR 1.60 (1.39-1.84) (m) vs RR 2.06 (1.69-2.51) (w)
UV Low
33 877 243 CS I VI NA U U Mortality (NS): RR 2.43 (2.21-2.48) (m) vs RR 1.68 (1.56-1.8) (w)
Mortality (NS 3-5 years): RR 1.29 (0.88-1.69) (m) vs RR 1.55
(1.17-1.93)(w)
UV High
Are smoking cessation interventions effective in the elderly?
34 470 RCT I

U U VI U

88% vs 82% (try to smoking cessation 6 months) 40% vs 33 % (p<0.05) (smoking cessation 6 months)
88% vs 82% (p<0.05) (try to smoking cessation 12 months) 33% vs 31% (smoking cessation 12 months)
UV Low
35 177
92 (in treatment group)
RCT I U U I U OR 2.24 (CI 95%; 1.07-4.69) (w) UV Low
36 1 553
1 016 (in treatment group)
RCT I U U VI U
OR 1.1 (0.7-1.8) (control vs therapy 1) vs OR 1.7 (1.1-2.6)
(control vs therapy 2)
UV Low
37 315 (in treatment group) CS U U NA VI U HR 0.74 (CI 95%; 0.6-0.92) UV Low